NCT07671911Phase 3Recruiting

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

Study sponsor: Trevi Therapeutics

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2028-06Estimated
Enrollment · participants306Estimated
Source updated2026-09-14Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Recruitment status changed

− Before

Not yet recruiting

+ After

Recruiting

Check registry source